dc.contributor.author |
Arman Karakaya, Yeliz |
|
dc.contributor.author |
Gokoz Dogu, Gamze |
|
dc.contributor.author |
Baser Oncel, Sevin |
|
dc.contributor.author |
Gormez, Aysegul |
|
dc.contributor.author |
Bir, Ferda |
|
dc.date.accessioned |
2022-03-15T10:29:56Z |
|
dc.date.available |
2022-03-15T10:29:56Z |
|
dc.date.issued |
2021 |
|
dc.identifier.citation |
Karakaya, Y. A., Dogu, G. G., Oncel, S. B., Gormez, A., & Bir, F. (2021). Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma. Annals of Medical Research, |
en_US |
dc.identifier.uri |
http://hdl.handle.net/11616/55636 |
|
dc.description.abstract |
Aim: The excision repair cross-complementation group 1 (ERCC-1) protein is a potential prognostic biomarker of the efficacy of platinum-based chemotherapy in non–small-cell lung cancer (NSCLC). The purpose of this study was to evaluate the clinicopathology
and prognostic significance of ERCC-1 expression, ERCC-1 (19q13) amplification in NSCLC patients; and the relationship between platinum-based chemotherapy.
Materials and Methods: We used the ERCC-1 antibody to measure the level of expression of ERCC-1 protein by immunohistochemical analysis from 351 patients and ERCC-1 gene copy number was evaluated by fluorescence in situ hybridization (FISH) in tumors from 81 patients.
Results: ERCC-1 expression in tumor cells was positive in 312 patients (88.9%). The ERCC-1 amplification in tumor cells was positive in 58 patients (71.6%) out of 81. The ERCC-1 amplification was also more frequent in early-stage tumors than late-stage tumors (p = 0.025). In the patients with positive ERCC-1 expression, longer overall survival was associated with early stage NSCLC (p =0.001). Patients having adenocarcinoma with negative ERCC-1 expression demonstrated longer overall survival than patients with squamous cell carcinoma (p = 0.037).
Conclusion: Our study demonstrated that increased ERCC-1 amplification is not associated with ERCC-1 protein expression. High ERCC-1 expression in patients with early-stage NSCLC is a good prognostic factor, although it is a negative predictor, indicating treatment resistance, in patients with advanced-stage NSCLC receiving platinum-based chemotherapy. We suggest that patients having adenocarcinoma with negative ERCC-1 expression benefit more with platinum-based chemotherapies. |
en_US |
dc.language.iso |
eng |
en_US |
dc.rights |
info:eu-repo/semantics/openAccess |
en_US |
dc.title |
Evaluation of survival and treatment correlation with ERCC-1 expression/amplification in Non-small cell carcinoma |
en_US |
dc.type |
article |
en_US |
dc.relation.journal |
Annals of Medical Research |
en_US |
dc.contributor.department |
İnönü Üniversitesi |
en_US |